MX2022007472A - Uso de plinabulina en combinacion con inhibidores de punto de control inmunitario. - Google Patents

Uso de plinabulina en combinacion con inhibidores de punto de control inmunitario.

Info

Publication number
MX2022007472A
MX2022007472A MX2022007472A MX2022007472A MX2022007472A MX 2022007472 A MX2022007472 A MX 2022007472A MX 2022007472 A MX2022007472 A MX 2022007472A MX 2022007472 A MX2022007472 A MX 2022007472A MX 2022007472 A MX2022007472 A MX 2022007472A
Authority
MX
Mexico
Prior art keywords
plinabulin
immune checkpoint
combination
checkpoint inhibitors
treating cancer
Prior art date
Application number
MX2022007472A
Other languages
English (en)
Inventor
Lan Huang
Gloria Tsi-Yie Lee
Original Assignee
Beyondspring Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beyondspring Pharmaceuticals Inc filed Critical Beyondspring Pharmaceuticals Inc
Publication of MX2022007472A publication Critical patent/MX2022007472A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

Se describen en la presente composiciones que comprenden Plinabulina y uno o más inhibidores de punto de control inmunitario para tratar cáncer. Algunas modalidades se refieren a métodos para tratar cáncer al co-administrar Plinabulina y uno o más inhibidores de punto de control inmunitario a un sujeto en necesidad del mismo.
MX2022007472A 2015-02-12 2017-08-10 Uso de plinabulina en combinacion con inhibidores de punto de control inmunitario. MX2022007472A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562115468P 2015-02-12 2015-02-12
US201562255259P 2015-11-13 2015-11-13

Publications (1)

Publication Number Publication Date
MX2022007472A true MX2022007472A (es) 2022-06-29

Family

ID=56615698

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017010338A MX2017010338A (es) 2015-02-12 2016-02-11 Uso de plinabulina en combinación con inhibidores de punto de control inmunitario.
MX2022007472A MX2022007472A (es) 2015-02-12 2017-08-10 Uso de plinabulina en combinacion con inhibidores de punto de control inmunitario.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017010338A MX2017010338A (es) 2015-02-12 2016-02-11 Uso de plinabulina en combinación con inhibidores de punto de control inmunitario.

Country Status (17)

Country Link
US (1) US20180028531A1 (es)
EP (1) EP3256130A4 (es)
JP (3) JP7243021B2 (es)
KR (1) KR20170117113A (es)
CN (2) CN117100753A (es)
AU (3) AU2016219204B2 (es)
BR (1) BR112017016902A2 (es)
CA (1) CA2975729A1 (es)
CL (1) CL2017002050A1 (es)
HK (1) HK1247816A1 (es)
IL (2) IL286282B2 (es)
MX (2) MX2017010338A (es)
MY (1) MY193968A (es)
NZ (1) NZ734256A (es)
RU (1) RU2723021C2 (es)
SG (1) SG11201706281YA (es)
WO (1) WO2016130839A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10441654B2 (en) 2014-01-24 2019-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. SMC combination therapy for the treatment of cancer
BR112017018964A2 (pt) 2015-03-06 2018-05-22 Beyondspring Pharmaceuticals Inc uso de plinabulin e métodos para tratar tumor cerebral
AU2016229294B2 (en) 2015-03-06 2021-11-04 Beyondspring Pharmaceuticals, Inc. Method of treating cancer associated with a RAS mutation
WO2016197204A1 (en) * 2015-06-11 2016-12-15 Bionomics Limited Pharmaceutical combination and uses thereof
DK3334726T3 (da) 2015-07-13 2022-05-16 Beyondspring Pharmaceuticals Inc Plinabulinsammensætninger
CA3013467A1 (en) 2016-02-08 2017-08-17 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
EP3463337A4 (en) 2016-06-06 2020-02-12 Beyondspring Pharmaceuticals, Inc. COMPOSITION AND METHOD FOR REDUCING NEUTROPENIA
EP3505183B1 (en) * 2016-08-26 2022-03-30 Tetsuji Okuno Microvascular blood flow decreasing agent and use thereof
JP2019530706A (ja) * 2016-10-14 2019-10-24 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 尿路上皮がんを治療するための、ｐｄ−１アンタゴニスト及びエリブリンの組合せ
WO2018129381A1 (en) 2017-01-06 2018-07-12 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
BR112019015974A2 (pt) 2017-02-01 2020-03-31 Beyondspring Pharmaceuticals, Inc. Método para reduzir neutropenia
NZ757213A (en) 2017-03-13 2022-01-28 Beyondspring Pharmaceuticals Inc Compositions of plinabulin and use thereof
JP6956254B2 (ja) * 2017-07-26 2021-11-02 チョン クン ダン ファーマシューティカル コーポレーション 血管遮断剤および免疫チェックポイント阻害剤を含む癌の予防または治療用の組成物
AU2018328773B2 (en) * 2017-09-08 2023-11-16 University Health Network Combination therapies for inhibition of Polo-like Kinase 4
CN109498627B (zh) * 2017-09-15 2021-06-04 深圳华大海洋科技有限公司 一种***的药物组合物及其应用
US11786523B2 (en) 2018-01-24 2023-10-17 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing thrombocytopenia
KR20210015875A (ko) * 2018-06-01 2021-02-10 비욘드스프링 파마수티컬스, 인코포레이티드. Egfr 돌연변이와 관련된 암을 치료하는 조성물 및 방법
CN108524442B (zh) * 2018-06-05 2022-01-28 深圳海王医药科技研究院有限公司 一种抗肿瘤药物的注射剂及其制备方法
CA3109223A1 (en) * 2018-08-16 2020-02-20 Beyondspring Pharmaceuticals, Inc. Method and composition for stimulating immune response
EP3873504B1 (en) * 2018-11-01 2023-12-13 North Carolina State University Adipocyte mediated delivery of anticancer therapeutics
CN110265095A (zh) * 2019-05-22 2019-09-20 首都医科大学附属北京佑安医院 用于hcc复发及rfs的预测模型和诺模图的构建方法及应用
CN112778155B (zh) * 2019-11-11 2023-08-11 大连万春布林医药有限公司 妥卡雷琐衍生物及其用途
MX2022013808A (es) * 2020-05-04 2023-02-09 Beyondspring Pharmaceuticals Inc Terapia de combinacion triple para mejorar la eliminacion de celulas cancerigenas en canceres con baja inmunogenicidad.
WO2022133492A1 (en) * 2020-12-18 2022-06-23 Beyondspring Pharmaceuticals, Inc. Compositions and methods for generating anti-tumor immune response
WO2022216908A1 (en) * 2021-04-09 2022-10-13 Beyondspring Pharmaceuticals, Inc. Therapeutic compositions and methods for treating tumors
CN113456643B (zh) * 2021-08-11 2022-04-01 遵义医科大学 一种含普那布林的药物组合及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL166628A0 (en) * 2002-08-02 2006-01-15 Nereus Pharmaceuticals Inc Dehydrophenyl lahistins and analogs thereof and the synthesis of dehydrophenyllahistins and analogs thereof
NZ548659A (en) * 2004-02-04 2011-01-28 Nereus Pharmaceuticals Inc Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
CA2607147C (en) * 2005-05-09 2018-07-17 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
US8569262B2 (en) * 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
WO2009089260A2 (en) * 2008-01-08 2009-07-16 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with tubulin modulating agents for the treatment of proliferative diseases
CA2774015A1 (en) * 2009-09-15 2011-03-24 Cerulean Pharma Inc. A cdp-camptothecin conjugate, particle or composition and uses thereof
US20130064831A1 (en) * 2010-05-17 2013-03-14 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
WO2012035436A1 (en) * 2010-09-15 2012-03-22 Tokyo University Of Pharmacy And Life Sciences Plinabulin prodrug analogs and therapeutic uses thereof
WO2013090552A1 (en) * 2011-12-13 2013-06-20 Yale University Compositions and methods for reducing ctl exhaustion
EP2911669B1 (en) * 2012-10-26 2024-04-10 The University of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
DK2958943T3 (da) * 2013-02-20 2019-12-09 Univ Pennsylvania Behandling af cancer ved anvendelse af humaniseret anti-EGFRvIII kimær antigenreceptor
CA2909052A1 (en) * 2013-06-03 2014-12-11 Novartis Ag Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor
MY185650A (en) * 2013-10-11 2021-05-27 Beyondspring Inc Cancer treatment with combinantion of plinabulin and taxane

Also Published As

Publication number Publication date
EP3256130A1 (en) 2017-12-20
KR20170117113A (ko) 2017-10-20
RU2723021C2 (ru) 2020-06-08
AU2016219204B2 (en) 2021-01-21
IL253784A0 (en) 2017-09-28
IL253784B (en) 2021-09-30
RU2017127966A3 (es) 2019-06-20
IL286282A (en) 2021-10-31
CN117100753A (zh) 2023-11-24
HK1247816A1 (zh) 2018-10-05
AU2021202416A1 (en) 2021-05-20
NZ734256A (en) 2019-02-22
RU2017127966A (ru) 2019-03-12
SG11201706281YA (en) 2017-09-28
MY193968A (en) 2022-11-03
JP2022190005A (ja) 2022-12-22
IL286282B2 (en) 2023-10-01
CL2017002050A1 (es) 2018-04-13
JP2021050247A (ja) 2021-04-01
NZ750444A (en) 2021-03-26
AU2021202416B2 (en) 2024-02-15
BR112017016902A2 (pt) 2018-03-27
JP7157181B2 (ja) 2022-10-19
US20180028531A1 (en) 2018-02-01
JP2018508572A (ja) 2018-03-29
IL286282B1 (en) 2023-06-01
WO2016130839A1 (en) 2016-08-18
JP7243021B2 (ja) 2023-03-22
CA2975729A1 (en) 2016-08-18
AU2016219204A1 (en) 2017-08-24
CN107427510A (zh) 2017-12-01
EP3256130A4 (en) 2018-08-01
MX2017010338A (es) 2017-12-20
AU2024200672A1 (en) 2024-02-22

Similar Documents

Publication Publication Date Title
MX2022007472A (es) Uso de plinabulina en combinacion con inhibidores de punto de control inmunitario.
IL272877A (en) SHP2 inhibitory compositions and methods for cancer treatment
ZA202208792B (en) Methods of treating and preventing graft versus host disease
MX2018008052A (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
IL249658A0 (en) Methods of treating cancer using tigit inhibitors and anticancer agents
BR112015011756A2 (pt) inibidores da glutamase e métodos de uso
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
PH12019501763A1 (en) Method of reducing neutropenia
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
MX2017006015A (es) Composiciones para usar en el tratamiento de cancer renal.
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
CL2016000326A1 (es) Composiciones y método para tratar condiciones asociadas con el complemento
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
IL251761B (en) A combination of alpha thymosin and a pd-1 inhibitor is beneficial in the treatment of cancer
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
MX2018005825A (es) Celulas inmunes modificadas y usos de las mismas.
PH12016501838A1 (en) Compounds and their methods of use
MX2015013021A (es) 5-bromo-indirrubinas.
MX2017014084A (es) Formulaciones de deposito inyectables.
PH12017501022A1 (en) Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same
GEP20217236B (en) Composition comprising pentose and polyphenolic compound
MX2020002585A (es) Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer.
MX2016009665A (es) Composiciones y metodos para el tratamiento de la hemorragia cerebral.
MX2017014893A (es) Composicion herbal para el tratamiento del dolor de espalda.
EA201691907A1 (ru) Комбинированная терапия кураксинами